Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models

BACKGROUND: Doxorubicin (DXR) hydrochloride (HCl) liposome injection is an important part of the treatment armamentarium for a number of cancers. With growing needs for affordable and effective anticancer treatments, the development of generics is becoming increasingly important to facilitate patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Burade, Vinod, Bhowmick, Subhas, Maiti, Kuntal, Zalawadia, Rishit, Ruan, Harry, Thennati, Rajamannar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461687/
https://www.ncbi.nlm.nih.gov/pubmed/28587612
http://dx.doi.org/10.1186/s12885-017-3377-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461687/
https://www.ncbi.nlm.nih.gov/pubmed/28587612
http://dx.doi.org/10.1186/s12885-017-3377-3

Ejemplares similares